From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | ADA starters (n = 46) | ETN starters (n = 46) | Effect estimate for ADA vs. ETN (95% CI) |
---|---|---|---|
Decrease in VAS well-being compared to baseline, median (IQR) | 2.0 (0.0 – 4.0) | 2.0 (0.1 – 5.0) | -0.81 (-1.72 – 0.08)a |
Decrease in active joint count compared to baseline, median (IQR) | 2.5 (1.0 – 4.0) | 2.0 (1.0 – 6.0) n = 45 | 0.44 (-0.22 – 1.10)a |
Adverse events, n (%) | 15 (34.1%) n = 44 | 13 (28.3%) | 1.82 (0.59 – 5.60)b |
Uveitis events, n (%) | 0 (0.0%) | 1 (2.2%) | - |